Concepedia

Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes

Tina Vilsbøll, Milan Zdravkovic, T Le-Thi, Thure Krarup, Ole Schmitz, J.P. Courrèges, Rob H.A. Verhoeven, Ingrid Bugáňová, Sten Madsbad

Diabetes Care · 2007 · 471 citations · 11 references

DOIFull text

Open access

Concepts

Abstract

iraglutide is a long-acting human glucagon-like peptide-1 (GLP-1) analog (1-4), and the current study was undertaken to evaluate efficacy and safety after 14 weeks' treatment with liraglutide in patients with type 2 diabetes.

References

11

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

The Lancet · 1998 · 20.1K citations

, , +13

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

R. C. Turner, Charles Fox, Matthews et al. · The Lancet · 1998 · 8.4K citations

, , +15

Standards of Medical Care in Diabetes–2006

Diabetes Care · 2006 · 974 citations · Full text

, , +17

Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration

Lotte Bjerre Knudsen, Per F. Nielsen, Per Olaf Huusfeldt et al. · Journal of Medicinal Chemistry · 2000 · 687 citations · Full text

, , +14

World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects

JAMA · 1997 · 673 citations

, , +12